The Buy rating and maintained $25 price target by HC Wainwright & Co. analyst Raghuram Selvaraju on Entrada Therapeutics (NASDAQ:TRDA) indicates a positive outlook for the stock. This news is directly related to TRDA and is important for investors as it reflects the analyst's confidence in the company's potential growth. The score of 1 suggests that the stock price is likely to go up in the short term.